上海百心安生物技术股份有限公司 近日，在意大利首都罗马核心区域，享有盛誉的 罗马圣彼得·法特贝内弗拉泰利医院 （Ospedale San Pietro FBF Roma）迎来临床重要突破，由经验丰富的 Dario Bertolone 医生与 Roberta Serdoz 医生领衔，并在心脏科主任 Francesco Monti 教授、导管室主任 Francesco Rotolo 教授的全 程指导与支持下， 首次成功应用 铂睿时 beris ® RDN 系统 完成了两例经桡动脉入路（TRA）RDN 手术 。 此次创举不仅标志着该院高血压介入治疗正式迈入经桡微创、安全高效的新阶段，更成为推动意大利首都高端医疗中心微创 RDN 技术发展的重要标杆。 以下文章来源于百心安 Bioheart ，作者Bioheart 百心安 Bioheart . 病例二 患者为 73 岁男性，因长期服用4种抗压药物控制不佳，接受铂睿时 Iberis ® RDN 系统治疗。手术同样采用左桡动脉入路（TRA），配合 Cordis MP1 125 cm 指引导管 与 Boston Scientific Choice 300 cm 指引导丝顺利 ...

以下文章来源于桡通心安 ，作者angiocare 桡通心安 . 上海安通医疗科技有限公司 近日，厄瓜多尔 CARDIOHEREDIA S.A. 医院在国际专家 Fausto Heredia 博士团队主刀下，采用 铂睿时 Iberis ® RDN 系统 ，成功为一名传统药物控制不佳、合并肾功能进行性损害慢性肾脏病 （CKD）的难治性高血压高危患者，完成一例 经桡动脉入路经皮去肾神经术（RDN） 。 术后患者血压显著下降、肾功能趋于稳定，既展现出血压控制与肾脏保护的双重获益，也为此类 高危人群提供了全新治疗路径与临床证据。 Iberis ® RDN 系统技术特征 Iberis ® RDN 系统采用多电极环形消融结构设计，具有良好的血管贴壁性和稳定性，可实现能量 在肾动脉周 向与纵向的更均匀分布，从而提高对肾动脉交感神经的消融充分性。 在降低周围组织热损伤风险的同时，亦有助于应对复杂血管解剖，为 RDN 操作的安全性和有效性提供了坚实 的技术保障。 循证依据：GSR-DEFINE 研究数据支持 本例的临床实践与疗效判断，均建立在坚实的循证医学研究基础之上。全球 SYMPLICITY 登记研究 GSR‑DEFINE ...

Core Viewpoint - The RDN (Renal Denervation) market is on the verge of explosive growth, driven by new guidelines and reimbursement decisions in the U.S. that include RDN as a treatment for resistant hypertension, indicating a significant commercial opportunity for the sector [3][4]. Group 1: Market Potential and Growth - The RDN market is projected to grow at a compound annual growth rate (CAGR) of 22% from 2023 to 2028, making it one of the fastest-growing segments in the medical device field [3]. - The long-term market potential for RDN in China is expected to exceed 10 billion yuan [3]. Group 2: Technological Developments - Recent FDA approvals for RDN products from Recor Medical and Medtronic mark a turning point for the technology, providing differentiated options in ultrasound and radiofrequency ablation [4]. - The introduction of the Iberis® RDN system by Bai Xin An, which is the only device approved for both transradial and transfemoral access, represents a significant innovation in the RDN space [5][6]. Group 3: Competitive Landscape - Chinese companies like Xinmai Medical, Meili Weiye, and Antong Medical have received approvals for their RDN products, showcasing the innovative capabilities of domestic firms [5]. - Blue Sail Medical, through its subsidiary Blue Sail Bosheng, has established a comprehensive international sales network, covering over 8,000 hospitals in more than 100 countries, positioning itself as a key player in the global market [6][10]. Group 4: International Expansion - The Iberis® RDN system has already seen successful clinical applications in various provinces in China and has completed its first commercial procedure in Europe [8]. - Collaborations between Chinese companies and international partners, such as Bai Xin An and Blue Sail Medical, are facilitating the entry of RDN products into overseas markets, with significant progress in countries like Germany, Spain, and Italy [9][11]. Group 5: Future Outlook - The RDN technology is set to lead a new era in hypertension treatment, with a vast unmet clinical need indicating substantial future market potential [11]. - Continuous innovation and international clinical collaborations are expected to enhance the global presence of Chinese RDN products, allowing them to capture a significant share of the high-end medical device market [11].